Barclays
DNLI icon

Barclays’s Denali Therapeutics DNLI Stock Holding History

Barclays’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22,500
Closed -$483K – 5145
2023
Q4 		$483K Buy
+22,500
New +$446K ﹤0.01% 3898

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's DNLI Position: Q2 2026 in Review

Barclays increased its Denali Therapeutics (DNLI) stake by 63% in Q2 2026, buying an estimated $674K and bringing the position to 84,892 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2294.

Barclays first reported a position in DNLI in Q1 2018 and has held it in 33 quarters since. The position peaked at $16.3M in Q4 2022. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Barclays held 84,892 shares of Denali Therapeutics worth $2.18M as of Q2 2026.
  • Barclays bought 32,808 Denali Therapeutics shares in Q2 2026, an estimated $674K.
  • Denali Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2294 holding.
  • Barclays first reported a position in Denali Therapeutics in Q1 2018 and has held it in 33 quarters since.
  • Barclays's Denali Therapeutics position peaked at $16.3M in Q4 2022.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.